Advances in the Treatment of Myelofibrosis: Clinical Trial Data of Next Generation Therapeutics – Live

Description

Program Description

---

Take Me to the Event Registration

This activity addresses advancements in managing patients with myelofibrosis (MF), including symptom recognition, prognostic risk scoring, and next-generation therapeutics for the treatment of MF.

The program will focus on the following:

MF – Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by clonal hematopoietic cell expansion with bone marrow fibrosis.

• Pathophysiology of MF
• Symptomology of MF based on myeloproliferative neoplasm symptom assessment (MPN-SAF)
• Prognostic scoring systems and risk assessment based on IPSS, DIPSS+, MIPSS70, Genetically Inspired IPSS, Myelofibrosis secondary to PV, and ET-prognostic model (MYSEC-PM)
• Molecular profiling of MF – Molecular profiling, cytogenetic and molecular characteristics.
• Prognostic scoring systems and risk assessment based on IPSS, DIPSS+, MIPSS70, Genetically Inspired IPSS, Myelofibrosis secondary to PV, and ET-prognostic model (MYSEC-PM)

Treatment Options for MF – NCCN guideline-directed treatment strategies for MF with JAK inhibitors and a first-in-class telomerase inhibitor.

• JAK Inhibitors
  • Ruxolitinib
  • Fedratinib
  • Pacritinib
• Newer Therapies – Ongoing Clinical Trials
  • PIM1 Kinase Inhibitor
    • Nuvisertib
  • Telomerase Inhibitor
    • Imetelstat (GRN163L)
  • Bromodomain and extraterminal domain (BET) inhibitor (BETi)
    • Pelabresib

Symptomatic patients with anemia and myelofibrosis

• Momelotinib, an activin A receptor type 1, and JAK1 and JAK2 have shown symptom, spleen, and anemia benefits in patients with MF
• Navitoclax (NAV) is an oral, small-molecule inhibitor of BCL-XL and BCL-2 that has a synergistic effect when used in combination with JAK inhibitors

Agenda

---

Overview of pathophysiology, symptom burden, risk stratification, and molecular profiling of MF
John Mascarenhas, MD

Discuss NCCN treatment guidelines-based treatment options, and next-generation therapeutics for the treatment of MF
Raajit K. Rampal, MD, PhD

Intended Audience

---

This activity is designed to meet the educational needs of hematologists/oncologists, community oncologists, physician assistants, nurse practitioners, nurses, and pathologists who manage patients with myelofibrosis.

Commercial Supporter

---